Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Marinus Pharmaceuticals
< Previous
1
2
3
4
Next >
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Today 16:04 EDT
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day
September 20, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024
September 12, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference
September 10, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024
August 19, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results
August 13, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2024 Financial Results on August 13, 2024
July 30, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Ganaxolone Approved in China as First Treatment for Seizures Associated with CDKL5 Deficiency Disorder
July 18, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status Epilepticus
June 17, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program
May 17, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
May 08, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference
May 02, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024
May 01, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
April 15, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
April 05, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review
March 27, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
March 05, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
February 21, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
February 20, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
February 16, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
January 04, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY® Net Product Revenue and Provides Business Update
January 04, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
December 07, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Seven Presentations at AES 2023, New Publication in Epilepsia and Results From the Second Generation Formulation MAD Study
November 20, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals to Present at the 6th Annual Evercore ISI HealthCONx Conference
November 14, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
November 09, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results
November 07, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Initiates Global Access Program for ZTALMY® (ganaxolone) Oral Suspension CV
November 07, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals to Provide Business Update and Report Third Quarter 2023 Financial Results on November 7, 2023
October 24, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
October 06, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.